Verastem logo
Verastem VSTM
$ 5.82 1.75%

Quarterly report 2025-Q3
added 11-04-2025

report update icon

Verastem Balance Sheet 2011-2026 | VSTM

Annual Balance Sheet Verastem

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-36.9 M -49.6 M -18.6 M - 92.1 M -9.41 M -62.9 M -32.3 M -24.9 M -33.9 M -18.9 M -10.1 M -21 M

Long Term Debt

40.1 M 24.5 M 2.26 M - 104 M 115 M 14.8 M - - - - - -

Long Term Debt Current

941 K 794 K 667 K 558 K 420 K - - - - - - - -

Total Non Current Liabilities

- - - - 108 M 116 M 15 M 341 K 516 K 679 K 11 K 58 K 68.7 M

Total Current Liabilities

26.4 M 21.7 M 18.6 M 17.1 M 29.9 M 37.1 M 17.1 M 11 M 10.1 M 9.2 M 7.8 M 2.4 M -

Total Liabilities

71.2 M 47.7 M 21.1 M 39.1 M 138 M 153 M 32.1 M 11.3 M 10.6 M 9.88 M 7.82 M 2.46 M 71.8 M

Retained Earnings

-825 M -738 M -664 M - -525 M -376 M -303 M -235 M -199 M -141 M -87.7 M -46.5 M -

Total Assets

150 M 95 M 109 M 154 M 145 M 277 M 89.8 M 83.6 M 113 M 98.6 M 125 M 92.9 M 59 M

Cash and Cash Equivalents

77.9 M 74.9 M 21.5 M 68 M 43.5 M 130 M 82.2 M 32.3 M 24.9 M 33.9 M 18.9 M 10.1 M 21 M

Book Value

78.5 M 47.4 M 87.6 M 115 M 7.17 M 124 M 57.7 M 72.3 M 102 M 88.8 M 117 M 90.5 M -12.8 M

Total Shareholders Equity

57.4 M 47.4 M 87.6 M 115 M 7.17 M 124 M 57.7 M 72.3 M 102 M 88.8 M 117 M 90.5 M -12.8 M

All numbers in USD currency

Quarterly Balance Sheet Verastem

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - 271 K 40.7 M 40.5 M 40.3 M 40.1 M 40.1 M 39.9 M 39.7 M 39.6 M 24.5 M 24.4 M 24.3 M 24.2 M 2.26 M 2.44 M 2.62 M 2.78 M 2.93 M 35.7 M 35.5 M 35.3 M 35.1 M 34.9 M 35.1 M 35.1 M 25.2 M 21.5 M 23.5 M 14.9 M 14.8 M 2.34 M 14.8 M 14.8 M - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

192 M 160 M 164 M 130 M 94.2 M 65.7 M 77.3 M 71.2 M 71.8 M 69 M 66.7 M 47.7 M 48.2 M 46.5 M 43.4 M 21.1 M 16.2 M 35.7 M 34.3 M 39.1 M 39.1 M 39.1 M 39.1 M 138 M 138 M 138 M 138 M 153 M 153 M 153 M 153 M 32.1 M 32.1 M 32.1 M 32.1 M 11.3 M 11.3 M 11.3 M 11.3 M - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - 327 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-1.13 B -1.03 B -1.01 B -956 M -891 M -867 M -859 M -825 M -798 M -778 M -753 M -738 M -721 M -703 M -681 M -664 M -647 M -624 M -608 M -593 M -593 M -593 M -593 M -525 M -525 M -525 M -525 M -376 M -376 M -376 M -376 M -303 M -303 M -303 M -303 M -235 M -235 M -235 M -235 M -199 M -199 M -199 M -199 M -141 M -141 M -141 M -141 M -87.7 M -87.7 M -87.7 M -87.7 M -46.5 M -46.5 M -46.5 M -46.5 M -14.5 M -14.5 M -14.5 M -14.5 M

Total Assets

177 M 196 M 132 M 102 M 126 M 106 M 124 M 150 M 176 M 192 M 121 M 95 M 111 M 100 M 116 M 109 M 112 M 124 M 137 M 154 M 154 M 154 M 154 M 145 M 145 M 145 M 145 M 277 M 277 M 277 M 277 M 89.8 M 89.8 M 89.8 M 89.8 M 83.6 M 83.6 M 83.6 M 83.6 M 113 M 113 M 113 M 113 M 98.6 M 98.6 M 98.6 M 98.6 M 125 M 125 M 125 M 125 M 92.9 M 92.9 M 92.9 M 92.9 M 59 M 59 M 59 M 59 M

Cash and Cash Equivalents

138 M 164 M 118 M 88.8 M 113 M 83.6 M 82.6 M 77.9 M 96.8 M 184 M 98.7 M 74.9 M 79.4 M 64.2 M 46.9 M 21.3 M 24.6 M 25.2 M 35.5 M 68 M 67.8 M 67.8 M 67.8 M 43.5 M 43.5 M 43.5 M 43.5 M 130 M 130 M 130 M 130 M 82.2 M 82.2 M 82.2 M 82.2 M 32.3 M 32.3 M 32.3 M 32.3 M 24.9 M 24.9 M 24.9 M 24.9 M 33.9 M 33.9 M 33.9 M 33.9 M 18.9 M 18.9 M 18.9 M 18.9 M 10.1 M 10.1 M 10.1 M 10.1 M 33.9 M 21 M 21 M 21 M

Book Value

-15.5 M 36.1 M -32.4 M -28.9 M 32.2 M 40 M 46.2 M 78.5 M 104 M 123 M 54.2 M 47.4 M 62.9 M 53.9 M 72.8 M 87.6 M 95.7 M 88.2 M 103 M 115 M 115 M 115 M 115 M 7.17 M 7.17 M 7.17 M 7.17 M 124 M 124 M 124 M 124 M 57.7 M 57.7 M 57.7 M 57.7 M 72.3 M 72.3 M 72.3 M 72.3 M 113 M 113 M 113 M 113 M 98.6 M 98.6 M 98.6 M 98.6 M 125 M 125 M 125 M 125 M 92.9 M 92.9 M 92.9 M 92.9 M 59 M 59 M 59 M 59 M

Total Shareholders Equity

-15.5 M 36.1 M -32.4 M -28.9 M 11.1 M 18.9 M 25.1 M 57.4 M 83.2 M 102 M 33 M 47.4 M 62.9 M 53.9 M 72.8 M 87.6 M 95.7 M 88.2 M 103 M 115 M 115 M 115 M 115 M 7.17 M 7.17 M 7.17 M 7.17 M 124 M 124 M 124 M 124 M 57.7 M 57.7 M 57.7 M 57.7 M 72.3 M 72.3 M 72.3 M 72.3 M 102 M 102 M 102 M 102 M 88.8 M 88.8 M 88.8 M 88.8 M 117 M 117 M 117 M 117 M 90.5 M 90.5 M 90.5 M 90.5 M -12.8 M -12.8 M -12.8 M -12.8 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Verastem, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.7 -1.24 % $ 2.61 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.84 7.59 % $ 4.58 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 166.38 1.52 % $ 8.28 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.82 5.82 % $ 1.14 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 8.73 3.44 % $ 1.37 B britainBritain
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 26.86 -3.83 % $ 719 M usaUSA
Codexis Codexis
CDXS
$ 1.02 0.99 % $ 74.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.8 -2.06 % $ 116 M franceFrance
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 3.13 -0.95 % $ 1.2 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 41.6 -0.17 % $ 1.32 B usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 35.97 0.76 % $ 3.74 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.88 3.47 % $ 2.92 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.35 -2.57 % $ 36.1 M usaUSA
Curis Curis
CRIS
$ 1.08 -5.26 % $ 6.81 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 40.68 -1.02 % $ 3.83 B usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 17.89 -2.03 % $ 859 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 6.07 2.71 % $ 82.9 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.72 -2.3 % $ 4.84 M usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 3.83 -10.09 % $ 244 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Daré Bioscience Daré Bioscience
DARE
$ 1.61 -5.29 % $ 13.7 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 23.25 10.77 % $ 2.26 B franceFrance
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 4.33 3.1 % $ 16.6 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
$ 3.34 0.3 % $ 1.2 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.77 -1.68 % $ 22.2 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Editas Medicine Editas Medicine
EDIT
$ 2.15 -2.27 % $ 177 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 2.28 3.64 % $ 7.29 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 29.2 -3.41 % $ 1.69 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Equillium Equillium
EQ
$ 1.92 5.49 % $ 66.7 M usaUSA